• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

    Jocelyn Aspa
    Mar. 29, 2019 09:53AM PST
    Biotech Investing

    Auris Medical (NASDAQ:EARS) has announced the first cohort of subjects have been randomized in its Phase 1b proof-of-concpet trial of AM201, which is the company’s investigational drug for preventing antipsychotic-induced weight gain and somnolence. As quoted in the press release: The Phase 1b trial with AM-201 is being conducted at one European site. The trial …

    Auris Medical (NASDAQ:EARS) has announced the first cohort of subjects have been randomized in its Phase 1b proof-of-concpet trial of AM201, which is the company’s investigational drug for preventing antipsychotic-induced weight gain and somnolence.

    As quoted in the press release:

    The Phase 1b trial with AM-201 is being conducted at one European site. The trial will enroll in total 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks. The protocol is based on a dose escalation with five different doses of intranasal betahistine. The primary efficacy outcome will be the reduction in weight gain and the secondary outcome will be the reduction in somnolence.

    “We are excited to have started the Phase 1b trial with AM-201 only five months after demonstrating significantly higher plasma levels with intranasal delivery of betahistine in a previous trial,” commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “We expect, if all goes well, to obtain top-line data from the trial during the third quarter and thus obtain swiftly the first proof-of-concept data with AM-201. Prior preclinical and clinical work with oral betahistine has already provided evidence for the compound’s effect on antipsychotic-induced weight gain and somnolence.”

    Click here to read the full press release.

    auris medicalnasdaq:ears
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Biotech Outlook: World Edition

    Biotech Outlook: World Edition

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×